logo

Michael Atkins, MD

Michael Atkins, MD

Oncology Boston, MA

Professor of Medical Oncology, Georgetown University

Office Address

Office Map
  • 330 Brookline Ave
    Kirstein 158
    Boston, MA 02215
    Phone: (616) 667-1930
    Fax: (617) 975-8030

Dr. Atkins's Clinical Specialties & Interests

  • Oncology: General Oncology

Dr. Atkins's Education & Medical Training

  • Tufts Medical CenterTufts Medical CenterFellowship, Hematology
  • Tufts Medical CenterTufts Medical CenterResidency, Internal Medicine
  • Tufts Univ Sch of MedTufts University School of MedicineMedical School

Dr. Atkins's Certifications & Licensure

  • DC State Medical LicenseDC State Medical License2012 - 2014
  • MA State Medical LicenseMA State Medical LicenseActive through 2013
  • American Board of Internal MedicineAmerican Board of Internal MedicineInternal Medicine
  • American Board of Internal MedicineAmerican Board of Internal MedicineMedical Oncology

Dr. Atkins's Clinical Trials

Dr. Atkins's Publications & Presentations

PubMed | Citations by Web of Science®

Grant Support

  • Career Development Program
    Career Development ProgramNational Cancer Institute
    2009 - 2011
  • Df/Hcc Kidney Cancer Spore
    Df/Hcc Kidney Cancer SporeNational Cancer Institute
    2009 - 2011
  • Developmental Research Program
    Developmental Research ProgramNational Cancer Institute
    2009 - 2011
  • Phase 1 Trial Of Twice Weekly IV IL-12 PLUS Low-Dose Subcutaneous IL-2
    Phase 1 Trial Of Twice Weekly IV IL-12 PLUS Low-Dose Subcutaneous IL-2National Center For Research Resources
    2004 - 2004
  • Df/Hcc Renal Cancer Spore
    Df/Hcc Renal Cancer SporeNational Cancer Institute
    2003 - 2008
  • Eastern Cooperative Oncology Group
    Eastern Cooperative Oncology GroupNational Cancer Institute
    2002 - 2012
  • Biologic Therapy Of Melanoma And Renal Cell Cancer
    Biologic Therapy Of Melanoma And Renal Cell CancerNational Cancer Institute
    2002 - 2006
  • Core--Clinical Data Management
    Core--Clinical Data ManagementNational Cancer Institute
    2002 - 2002
  • Chemo And Cytokine Immunotherapy In High Risk Melanoma
    Chemo And Cytokine Immunotherapy In High Risk MelanomaNational Cancer Institute
    2001 - 2002
  • Topical Tretinoin /Oral Fenretinide In Dysplastic Nevus
    Topical Tretinoin /Oral Fenretinide In Dysplastic NevusNational Center For Research Resources
    2000 - 2002
  • Ivrhil 12 W/ Or W/Out Test Dose In Patients W/ Advanced Malignancies
    Ivrhil 12 W/ Or W/Out Test Dose In Patients W/ Advanced MalignanciesNational Center For Research Resources
    1999 - 2002
  • CNI 1493 &Il 2 In Renal Cell Carcinoma &Melanoma Patients
    CNI 1493 &Il 2 In Renal Cell Carcinoma &Melanoma PatientsNational Center For Research Resources
    1999 - 2002
  • IL 2 Administered By IV In Patients With Advanced Malignant Melonoma
    IL 2 Administered By IV In Patients With Advanced Malignant MelonomaNational Center For Research Resources
    1998 - 1999
  • RH Interleukin 12 Administered Subcutaneously In Patients With Cancer
    RH Interleukin 12 Administered Subcutaneously In Patients With CancerNational Center For Research Resources
    1998 - 1999
  • Trial Of Concurrent Biochemotherapy W/ Cisplatin, Dacarbazine, Vinplastine, IL2
    Trial Of Concurrent Biochemotherapy W/ Cisplatin, Dacarbazine, Vinplastine, IL2National Center For Research Resources
    1998 - 1999
  • IL2 Administered By IV In Patients With Advanced Renal Cell Carcinoma
    IL2 Administered By IV In Patients With Advanced Renal Cell CarcinomaNational Center For Research Resources
    1998 - 2002
  • OPEN Label Non-Random Dose Escalation Study Of RH IL-12 Subcutaneous Injection
    OPEN Label Non-Random Dose Escalation Study Of RH IL-12 Subcutaneous InjectionNational Center For Research Resources
    1997 - 1997
  • Phase II Pilot Trial Of Concurrent Biochemotherapy With Cisplatin, Dacarbazine
    Phase II Pilot Trial Of Concurrent Biochemotherapy With Cisplatin, DacarbazineNational Center For Research Resources
    1997 - 1997
  • Phase I Trial Of High Dose Interleukin 2 With TNF Receptor IGG Chimera
    Phase I Trial Of High Dose Interleukin 2 With TNF Receptor IGG ChimeraNational Center For Research Resources
    1996 - 1997
  • Chemoprevention Of Prostate Cancer With Finasteride, Phase III Intergroup
    Chemoprevention Of Prostate Cancer With Finasteride, Phase III IntergroupNational Center For Research Resources
    1996 - 1998
  • Phase III, Randomized, Double Blind, Placebo Controlled Study Of Ct1501r
    Phase III, Randomized, Double Blind, Placebo Controlled Study Of Ct1501rNational Center For Research Resources
    1996 - 1996
  • Phase II Study Of Recombinant IL-6 Administered By ONE Hour Infusions
    Phase II Study Of Recombinant IL-6 Administered By ONE Hour InfusionsNational Center For Research Resources
    1996 - 1996
  • Phase I Dose Escalation Study Of Recombinant Human Interleukin 12
    Phase I Dose Escalation Study Of Recombinant Human Interleukin 12National Center For Research Resources
    1996 - 1996
  • Phase I Dose Escalating Study Of Recombinant Human Interleukin 12
    Phase I Dose Escalating Study Of Recombinant Human Interleukin 12National Center For Research Resources
    1996 - 1996
  • Multipart Phase I Clinical Trial Of High Dose IL 2 In Combination With IL 1
    Multipart Phase I Clinical Trial Of High Dose IL 2 In Combination With IL 1National Center For Research Resources
    1996 - 1996

Alternate Names

  • Dr. Michael Atkins, Dr. Michael Atkins, MD, Dr. M Atkins, Dr. Michael B. Atkins

33 Colleague Invites!
Is this you? If so, register to see 33 messages.

Physicians, view Dr. Atkins's full Doximity profile to:

  • Trade HIPAA-secure messages
  • Send and receive online faxes
  • Refer a patient
  • See their complete CV